Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and ADME of DA-1229 (Evogliptin) in Healthy Males
NCT02267902Phase 1Unknown
- Sponsor
- Dong-A ST
- Start
- Sep 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of DA5221-B2 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dong-A ST. Primary endpoints: Absolute Bioavailability of DA-1229 (F) at 240 hours and Mass Balance Recovery (Ae, %Ae) at 240 hours. Status: unknown.
02
Drugs
DA5221-B2
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02267902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02267902.